PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.
Alzheimer’s disease is caused by neurodegeneration resulting in cognitive decline, that has been linked to heightened systemic inflammation. Identification of the characteristic amyloid-β (Aβ) plaques in the brain is either by positron-emission tomography (PET) imaging or through its measurement in cerebrospinal fluid (CSF). A minimally invasive, cost-effective test that measures blood-based biomarker could predict the onset of Alzheimer’s earlier and therefore start therapies to improve patient prognosis. To this end, we have developed lateral-flow tests that measure vascular biomarkers, ICAM-1 and VCAM-1 and have validated their clinical use with serum samples.
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.
The alert did not successfully save. Please try again later.
Alice Iles, Peijun He, Ioannis Katis, Panagiotis Galanis, Jessica Teeling, Robert Eason, Collin Sones, "Monitoring neurodegenerative diseases using paper-based lateral-flow devices," Proc. SPIE PC11940, Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic and Photobiomodulation Therapy XXX, (7 March 2022); https://doi.org/10.1117/12.2603877